Abstracts

ADVERSE OUTCOMES IN SUBSEQUENT PREGNANCIES IN THE IMPAACT 2010 TRIAL

Few studies have prospectively captured pregnancy outcomes among women living with HIV (WLHIV) who conceive on antiretroviral treatment (ART). IMPAACT 2010 (VESTED) enrolled 643 WLHIV at 14-28 weeks gestational age in 9 countries. Women were randomized to start ART with dolutegravir (DTG) plus emtricitabine (FTC)/tenofovir alafenamide (TAF); DTG+FTC/tenofovir disoproxil fumarate (TDF); or efavirenz (EFV)/FTC/TDF. Due…

IMPACT OF MATERNAL HIV/HBV COINFECTION ON PREGNANCY AND INFANT OUTCOMES

The impact of maternal HIV/HBV coinfection on the risk of adverse pregnancy and infant outcomes remains understudied. We compared adverse pregnancy and infant outcomes among women living with HIV/HBV versus HIV alone, randomized antepartum to three of antiretroviral (ARV) perinatal transmission regimens in the IMPAACT PROMISE study. ARV-naïve pregnant women with HIV from Africa and…

HIV-RELATED DIFFERENCES IN PLACENTAL IMMUNOLOGY: DATA FROM THE PRACHITi COHORT

HIV-exposed and uninfected (HEU) infants have a higher risk of death than HIV-unexposed and uninfected infants, mostly from infections. We hypothesized that maternal HIV infection, even when virally suppressed, affects placental immunology and expression of FcRn, a receptor that facilitates maternal-fetal transmission of antibodies. We conducted an observational study of 234 pregnant women with and…

PERINATAL HIV-1 TRANSMISSION IN FRANCE: U=U FOR MOTHERS ON ART FROM CONCEPTION

Antiretroviral therapy (ART) is remarkably effective to prevent perinatal transmission (PT) of HIV-1. We sought to evaluate the transmission rate in population in a context of generalized ART before conception. The analysis included 14,630 HIV-1-infected mothers- delivering from 2000 to 2017 in centers participating in the nationwide prospective multicenter French Perinatal Cohort (ANRS-EPF). PT was…

RAPID SEMI-QUANTITATIVE ANTIGEN TESTING AND MORTALITY IN CRYPTOCOCCAL MENINGITIS

Mortality rates in individuals with HIV-associated cryptococcal meningitis (CM) remain high in sub-Saharan Africa, with 25-50% of individuals dying within 10 weeks of diagnosis despite antifungal therapy. Stratifying patients with CM into higher and lower risk groups could help guide management and target at-risk individuals for more intensive care. The BIOSYNEX® CryptoPS is a semi-quantitative,…

ACTG A5351S: EFFECT OF IMMUNE-MODULATORY INTERVENTIONS ON CMV REPLICATION DURING ART

Two trials explored the effect of immune-modulators on inflammation in people with HIV (PWH) on suppressive ART. A5336 (ruxolitinib vs placebo) revealed decreased immune activation (sCD14, CD38+HDR+ on CD4+ T Cells) and cell survival (Bcl-2). A5337 (sirolimus, single arm) revealed decreased cellular cycling (Ki67+) and CD4+ T-cell HIV DNA. Here, we investigate if these immune-modulators…